JLJiing-Chyuan Luo

Jiing-Chyuan Luo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiing-Chyuan Luo has a total of 183 co-authors. Here are the top co-authors by number of shared publications:

  • Ming-Chih Hou

    School of Medicine, National Yang Ming Chiao Tung University

    26 shared publications
  • Fa-Yauh Lee

    Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC

    22 shared publications
  • Xi-Hsuan Lin

    Department of Medicine, National Yang Ming Chiao Tung University Hospital, Yilan, Taiwan, ROC

    14 shared publications
  • Han-Chieh Lin

    Department of Medicine, National Yang-Ming University, School of Medicine, Taipei, Taiwan; Division of Gastroenterology, Taipei Veterans General Hospital, Taipei, Taiwan

    13 shared publications
  • Yi-Hsiang Huang

    School of Medicine, National Yang Ming Chiao Tung University

    9 shared publications
  • Tseng-Shing Chen

    Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC

    8 shared publications

Latest Publications

  • Open Access

    Integrated microbiome and metabolomic profiling reveals alterations across the adenoma–colorectal cancer sequence

    by Tien-En Chang, Hung-Hsin Lin, Jiing-Chyuan Luo, Ying-Fan Chen, Yen-Po Wang, Kuei-Chuan Lee, Pei-Chang Lee, Yi-Tsung Lin, Hui-Chun Huang, Chien-Wei Su, et al.

    The incidence of colorectal cancer (CRC) has been increasing in Taiwan and is associated with multiple risk factors. Increasing evidence suggests that gut microbiota dysbiosis contributes to CRC development. This study aimed to characterize microbial and metabolic alterations across premalignant and malignant colorectal lesions and to identify potential microbiome-associated biomarkers. Individuals undergoing colonoscopy for screening or surveillance at Taipei Veterans General Hospital were enrolled. Gut microbial composition was analyzed using full-length 16S rRNA gene sequencing to achieve high-resolution taxonomic profiling. Predicted functional pathways were inferred from microbial communities, and targeted metabolomic profiling was performed to evaluate microbial metabolic outputs. A total of 122 individuals were included, comprising 62 healthy controls, 15 adenoma cases, and 45 CRC cases. Change in microbial composition and predicted functional pathways were observed across the control, adenoma, and CRC groups. Control-associated taxa were linked to carbohydrate fermentation and amino acid metabolism pathways, whereas CRC-associated taxa, particularly Fusobacterium, showed broad negative correlations with multiple biosynthetic pathways. Metabolomic analysis showed increased tauro-ursocholanic acid and reduced short-chain fatty acids (SCFAs) in CRC. CRC-associated bacteria were negatively correlated with SCFAs and positively correlated with several bile acid metabolites, including lithocholic acid, murocholic acid, tauro-ursocholanic acid, and taurohyocholic acid. Integrative analysis of full-length 16S rRNA sequencing, predicted functional pathways, and metabolomic profiling identified microbial and metabolic differences across the control, adenoma, and CRC groups. These findings are consistent with an association between gut microbial alterations and colorectal neoplasia and may inform future studies of microbial and metabolic biomarkers for CRC. IMPORTANCE: Colorectal cancer (CRC) develops through an adenoma–carcinoma sequence, yet the microbial and metabolic alterations accompanying this progression remain incompletely understood. In this study, we integrated full-length 16S rRNA gene sequencing with metabolomic profiling to characterize taxonomic, functional, and metabolic changes across healthy controls, adenoma, and CRC. Our results showed coordinated changes in microbial taxa, predicted metabolic pathways, and fecal metabolites across the control, adenoma, and CRC groups. Control-associated taxa were linked to pathways related to carbohydrate fermentation and amino acid metabolism, whereas CRC-associated taxa, particularly Fusobacterium, showed negative correlations with several biosynthetic pathways. In addition, CRC-associated taxa were associated with reduced short-chain fatty acids (SCFAs) and increased levels of certain bile acid-related metabolites. These findings suggest an association between microbiome-associated metabolic alterations and colorectal neoplasia and support further investigation of microbial and metabolic biomarkers.

  • Continuous Versus Bolus Terlipressin for Acute Oesophageal Variceal Bleeding and Hepatorenal Syndrome in Cirrhosis: Meta‐Analysis

    by Ping‐Han Hsieh, Tsung‐Chieh Yang, Enoch Yi‐No Kang, Yu‐Fu Chen, Pei‐Chang Lee, Kuei‐Chuan Lee, Hui‐Chun Huang, Jiing‐Chyuan Luo, Ming‐Chih Hou

    Background & Aims: Terlipressin is crucial for treating acute oesophageal variceal bleeding (AEVB) and hepatorenal syndrome (HRS). This meta‐analysis compared the continuous versus bolus terlipressin infusion for treating the above conditions in patients with cirrhosis. Methods: Three major databases were searched for randomised controlled trials (RCTs) comparing two infusion strategies. A meta‐analysis was conducted to estimate the risk ratios (RR) with a 95% confidence interval (CI) based on a random‐effects model. Subgroup analyses were performed to account for adverse events (AEs) in terms of severity and organ systems. Additionally, a dose–response analysis was conducted to evaluate the correlation between drug dosage and AEs. Result: Six RCTs (494 patients) were included. Compared with bolus infusion, continuous terlipressin infusion showed less treatment failure (RR, 0.32; 95% CI, 0.12–0.87; p = 0.03), less rebleeding (RR, 0.52; 95% CI, 0.33–0.81; p < 0.01) and a trend toward lower mortality (RR, 0.62; 95% CI, 0.30–1.28; p = 0.19) in patients with AEVB, while response rates were comparable in patients with HRS (RR, 1.11; 95% CI, 0.87–1.41; p = 0.40) and a risk reduction of total AEs (RR, 0.59; 95% CI, 0.45–0.76; p < 0.01). Subgroup analyses stratifying AEs supported these findings, and a correlation was noted between drug dose and cardiovascular AEs. Conclusion: Compared to bolus administration, continuous terlipressin infusion reduces treatment failure and rebleeding rates in patients with AEVB; provides a comparable response rate in patients with HRS; and decreases the incidence of total, severe, and cardiovascular AEs while allowing for lower overall doses.

  • Open Access

    The Impact of Esophagogastric Varices on the Outcomes of Patients With Cholangiocarcinoma

    by Tzu-Han Ma, Yu-Jen Chen, Chun-Ting Ho, Pei-Chang Lee, Tsung-Chieh Yang, Hui-Chun Huang, Yi-Hsiang Huang, Ming-Huan Chen, Jiing-Chyuan Luo, Ming-Chih Hou, et al.

    INTRODUCTION: Esophagogastric varices (EGV) are known to correlate with a poorer prognosis in patients with liver cirrhosis or hepatocellular carcinoma. However, their clinical significance in patients with cholangiocarcinoma (CCA) remains unknown. The aim of this study was to investigate the impact of EGV on the outcomes of patients with CCA. METHODS: This retrospective study enrolled 923 consecutive treatment-naive patients diagnosed with CCA between January 2013 and December 2023. Among these, 321 patients received esophagogastroduodenoscopy at the time of CCA diagnosis. The primary end point was to assess the impact of EGV on overall survival (OS) in patients with CCA, whereas the secondary end point was to identify the predictive factors for the occurrence of EGV. RESULTS: Of the patients analyzed, 47 (14.6%) were diagnosed with EGV by esophagogastroduodenoscopy. Among these, 39 patients did not receive primary prophylaxis for EGV bleeding and were classified as the EGV group, whereas the remaining 274 patients (85.4%) formed the non-EGV group. The median OS was shorter in the EGV group than that in the non-EGV group (182 vs 357 days, P = 0.009). Multivariate analyses identified the presence of EGV as an independent risk factor of poorer OS (hazard ratio 1.823, confidence interval 1.248–2.663, P = 0.002). Besides, fibrosis-4 scores >2.67 and albumin-bilirubin grades >1 were predictive factors for EGV occurrence. DISCUSSION: While the prevalence of concurrent EGV in patients with CCA was relatively low, its presence was associated with a poorer prognosis. The fibrosis-4 scores and albumin-bilirubin grades predicted the occurrence of EGV.


  • Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy

    by Pei-Chang Lee, Chi-Jung Wu, Ya-Wen Hung, Chieh-Ju Lee, Hsien-Chen Mon, Chen-Ta Chi, I-Cheng Lee, Yu-Lun Kuo, Shih-Hsuan Chou, Jiing-Chyuan Luo, et al.

    Background and Aims: Gut microbiota could modulate the outcome of cancer immunotherapy, including HCC. Although metabolic dysfunction–associated steatotic liver disease-related HCC (MASLD-HCC) and viral hepatitis-related HCC (V-HCC) exhibit different tumor microenvironments and gut microbiome composition, both respond to combination immunotherapy. This study aimed to investigate whether distinct microbiota/metabolomic signatures are associated with outcomes of combination immunotherapy in MASLD-HCC and V-HCC, separately. Approach and Results: Between January 2021 and April 2024, 77 V-HCC patients and 25 with MASLD-HCC initiating first-line combination immunotherapy were prospectively enrolled. Pre-treatment fecal microbiota/metabolites and serum cytokines/chemokines were analyzed in association with durable tumor response, overall survival (OS) and progression-free survival (PFS). MASLD-HCC patients showed predominant fecal Bacteroides ovatus , Kluyvera georgiana , Klebsiella oxytoca , and Enterococcus faecium , with lower levels of short-chain fatty acids (SCFAs) and ursodeoxycholic acid (UDCA) compared to V-HCC. Durable responders (DRs) of MASLD-HCC had enriched Mediterraneibacter gnavus ATCC 29149 and significantly higher SCFAs (acetate, propionate, butyrate, and isobutyrate) and UDCA. In contrast, V-HCC-DRs were characterized by predominant Bifidobacterium and similarly enriched SCFAs. In both MASLD-HCC and V-HCC, fecal acetate level was a common significant predictor of DR, PFS, and OS. Patients with higher acetate levels had significantly longer OS (median: 25.2 vs. 11.3 mo; p p <0.001). Conclusions: Distinct gut microbiota, but shared beneficial metabolites, particularly fecal acetate, are associated with durable response to combination immunotherapy and improved survival in both MASLD-HCC and V-HCC. Fecal acetate may serve as a potential biomarker and therapeutic target for optimizing HCC treatment.


  • Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV‐related hepatocellular carcinoma undergoing radiofrequency ablation

    by Kuo‐Cheng Wu, I‐Cheng Lee, Chen‐Ta Chi, Chien‐An Liu, Nai‐Chi Chiu, Shao‐Jung Hsu, Pei‐Chang Lee, Chi‐Jung Wu, Jiing‐Chyuan Luo, Ming‐Chih Hou, et al.

    Summary: Background: The benefits of HCV eradication on distinct recurrence patterns and long‐term hepatic outcomes in patients with hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA) remain uncertain. This study aims to assess the impact of HCV eradication on HCC recurrence patterns and long‐term hepatic outcomes after RFA and to identify predictors of recurrence in patients achieving sustained virological response (SVR).Methods: We retrospectively enrolled 274 patients receiving RFA for HCV‐related HCC, including 73 and 88 patients treated with interferon‐based (IFN) and direct‐acting antivirals (DAA) therapy, respectively. We analysed factors associated with local tumour progression (LTP), distant recurrence, overall survival, and hepatic decompensation.Results: SVR was achieved in 49.3% of patients undergoing IFN therapy and 93.2% of patients undergoing DAA therapy. HCV eradication was not associated with LTP but significantly correlated with reduced risk of distant recurrence (by DAA: hazard ratio (HR) = 0.449, p = 0.006), overall survival (by IFN: HR = 0.242, p < 0.001; by DAA: HR = 0.274, p < 0.001) and hepatic decompensation (by IFN: HR = 0.313, p = 0.004; by DAA: HR = 0.281, p < 0.001). The benefits of achieving SVR in terms of overall survival and hepatic decompensation remained significant in subgroups of patients with and without recurrence. Patients with SVR showed a significant decline in FIB‐4 score and a higher proportion of ALBI grade improvement. Among SVR patients, the IMbrave050 criteria predicted LTP but not distant recurrence, whereas the FIB‐4 score after SVR, rather than the baseline FIB‐4, predicted distant recurrence.Conclusions: HCV eradication was associated with a significant reduction in distant recurrence, mortality and hepatic decompensation following RFA in patients with HCV‐related HCC.


  • Open Access

    The alteration of fecal microbial and metabolic profile of gallstone patients in Taiwan: Single-center study

    by Tien-En Chang, Kuo-Hung Huang, Jiing-Chyuan Luo, Yi-Hsiang Huang, Hung-Hsin Lin, Wen-Liang Fang, Ming-Chih Hou

    Background: Gallstone disease is a common health problem worldwide. The role of the gut microbiota in gallstone pathogenesis remains obscure. Our aim was to evaluate the association and crosstalk between gut microbiota, gut metabolomic, and metabolic parameters in cholesterol gallstone patients, pigmented gallstone patients, and controls. Methods: We collected stool samples from healthy individuals and patients with gallstones in our hospital from March 2019 to February 2021. 16s rRNA sequencing was performed, followed by differential abundance analyses. Measurement of bile acids and short-chain fatty acids was conducted via targeted metabolomics. Result: Thirty healthy individuals and 20 gallstone patients were recruited. The intergroup difference of microbial composition was significant between control and gallstone patients. The control group had more abundant Faecalibacterium, Prevotella 9, and Bacteroides plebeius DSM 17135. The cholesterol stones group had higher Desulfovibrionaceae and Bacteroides uniformis than the other two groups, while the pigment stone group had more abundant Escherichia-Shigella. In the analysis of metabolites, only n-butyric acid had a significantly higher concentration in the controls than in the gallstone group (p < 0.01). The level of 3α-hydroxy-12 ketolithocholic acid, deoxycholic acid, and cholic acid showed no intergroup differences but was correlated to the serum cholesterol level and bacterial richness and evenness. Conclusion: Our study revealed the key taxa that can discriminate between individuals with or without gallstones. We also identified metabolites that are possibly associated with metabolic parameter and bacterial diversity. However, the correlation of the metabolites to certain clusters of bacteria should be analyzed in a larger cohort.


  • Open Access

    Assuring safety of fecal microbiota transplantation in the COVID‐19 era: A single‐center experience

    by Tien‐En Chang, Kuei‐Chuan Lee, Pei‐Chang Lee, Yen‐Po Wang, Yi‐Tsung Lin, Hui‐Chun Huang, Jiing‐Chyuan Luo, Hsiang‐Ling Ho, Yi‐Hsiang Huang, Ming‐Chih Hou, et al.

    Background and Aim: Fecal microbiota transplantation (FMT) is used to treat recurrent or refractory Clostridioides difficile infection (CDI). In the past, screening of fecal donors required surveillance of personal behavior, medical history, and diseases that could be transmitted by the blood or fecal-oral route. In addition, the exclusion of multidrug-resistant organisms (MDROs) has been recommended since 2018. This task has become more complicated in the era of the coronavirus disease-2019 (COVID-19) pandemic. To prevent fecal transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is crucial to commence screening for SARS-CoV-2, alongside other traditional tests. Our aim was to investigate whether hidden carriers of SARS-CoV-2 were enrolled for stool donation, and the status of the presence or incidence of MDRO during fecal donation in Taiwan.Methods: Fecal products collected from March 2019 to December 2022 were tested for MDRO and nucleic acid amplification tests for SARS-CoV-2 using the pooling method. The period of fecal product collection crossed the time before and during the COVID pandemic in Taiwan.Results: A total of 151 fecal samples were collected. The fecal products were tested using polymerase chain reaction (PCR) to detect SARS-CoV-2. The results were negative for all stocks. This was similar to the results of MDRO testing. The safety of FMT products has been guaranteed during the pandemic.Conclusion: Our FMT center produced MDRO-free and COVID-19-free products before and during the COVID-19 outbreak in Taiwan. Our protocol was effective for ensuring the safety of FMT products.


  • Open Access

    Fecal microbiota profile in patients with inflammatory bowel disease in Taiwan

    by Tien-En Chang, Jiing-Chyuan Luo, Ueng-Cheng Yang, Yi-Hsiang Huang, Ming-Chih Hou, Fa-Yauh Lee

    Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disease associated with complicated interaction between immune, gut microbiota, and environmental factors in a genetically vulnerable host. Dysbiosis is often seen in patients with IBD. We aimed to investigate the fecal microbiota in patients with IBD and compared them with a control group in Taiwan. Methods: In this cross-sectional study, we investigated fecal microbiota in 20 patients with IBD and 48 healthy controls. Fecal samples from both IBD patients and controls were analyzed by the next-generation sequencing method and relevant software. Results: The IBD group showed lower bacterial richness and diversity compared with the control group. The principal coordinate analysis also revealed the significant structural differences between the IBD group and the control group. These findings were consistent whether the analysis was based on an operational taxonomic unit or amplicon sequence variant. However, no significant difference was found when comparing the composition of fecal microbiota between ulcerative colitis (UC) and Crohn’s disease (CD). Further analysis showed that Lactobacillus, Enterococcus, and Bifidobacterium were dominant in the IBD group, whereas Faecalibacterium and Subdoligranulum were dominant in the control group at the genus level. When comparing UC, CD, and control group, Lactobacillus, Bifidobacterium, and Enterococcus were identified as dominant genera in the UC group. Fusobacterium and Escherichia_Shigella were dominant in the CD group. Conclusion: Compared with the healthy control, the IBD group showed dysbiosis with a significant decrease in both richness and diversity of gut microbiota.


  • Open Access

    Differences in intestinal microbiota profiling after upper and lower gastrointestinal surgery

    by Xi-Hsuan Lin, Ueng-Cheng Yang, Jiing-Chyuan Luo, Tien-En Chang, Hung-Hsin Lin, Chi-Wei Huang, Jen-Jie Chiou, Wen-Liang Fang, Kuo-Hung Huang, Yi-Hsiang Huang, et al.

    Background: We aimed to investigate the long-term effects of metabolic profiles and microbiota status in patients after upper gastrointestinal (GI) surgery and lower GI surgery and compared them with a control group. Methods: In this cross-sectional study, we analyzed the occurrence of metabolic syndrome (MS) in 10 patients who underwent curative total gastrectomy with Roux-en-Y esophagojejunostomy (RYEJ) anastomosis, 11 patients who underwent curative partial colectomy with right hemicolectomy (RH), and 33 age- and sex-matched controls. Fecal samples were also analyzed by a next-generation sequencing method. Results: Compared with the control group, the occurrence of MS was significantly lower among patients who underwent total gastrectomy with RYEJ than the controls over the long-term follow-up (>8 years; p < 0.05). Patients who received RH only had a trend of higher serum fasting glucose (p = 0.10). The diversity of the gut microbiota significantly decreased after RH in comparison with the control group and RYEJ group, respectively (p < 0.05). Principal component analysis revealed significant differences between the control, RYEJ, and RH groups (p < 0.001). At the genus level, the ratio of Prevotella to Bacteroides (P/B) was significantly higher in the RYEJ group than in the control group, whereas the P/B ratio was significantly lower in the RH group than in the control group (p < 0.05). Conclusion: Early gastric cancer patients who received total gastrectomy with RYEJ had a lower occurrence of MS than the controls, while early colorectal cancer patients who received RH were associated with a higher serum fasting glucose than the controls during long-term follow-up. In parallel with the metabolic differences, the P/B ratio was also significantly altered in patients after upper and lower GI surgery.


  • Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study

    by Xi‐Hsuan Lin, Jiing‐Chyuan Luo, Po‐Hsiang Ting, Tien‐En Chang, Yi‐Hsiang Huang, Ming‐Chih Hou, Fa‐Yauh Lee

    Background and Aim The prospective, open-label, randomized study aims to compare the efficacy of lansoprazole, a fast orally disintegrating proton pump inhibitor (PPI), and dexlansoprazole, a dual delayed release PPI, in patients with atypical symptoms of gastroesophageal reflux disease (GERD). Methods Patients with atypical GERD symptoms with a total reflux symptom index score > 10 were eligible for enrollment. From February 2018 to December 2019, 232 subjects were randomly assigned (1:1 ratio) to receive oral lansoprazole, Takepron OD 30 mg, once daily before breakfast or oral dexlansoprazole, Dexilant 60 mg, once daily before breakfast for 8 weeks. The primary end-point is to compare the symptoms response rate after an 8-week PPI therapy between the two groups. Results There were 232 study subjects enrolling in this study. After the 8-week PPI therapy, dexlansoprazole-treated group had a significantly higher response rate than lansoprazole-treated group in cough (76.5% vs 38.0%) and globus (69.7% vs 30.8%) (P all < 0.05 by intention-to-treat). Multivariate logistic regression analysis showed that the use of dexlansoprazole, presence of dyslipidemia, and typical GERD symptoms (acid reflux and heartburn) were predictors for symptom response for cough; the use of dexlansoprazole and presence of erosive esophagitis were predictors for symptom response for globus (P all < 0.05). No predictor for therapy response to hoarseness was noted. Conclusions There is a higher response rate for cough and globus symptoms in patients with atypical GERD after the 8-week PPI therapy with dexlansoprazole rather than lansoprazole.